Healthcare [ 5/11 ] | Medical Devices [ 31/112 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 1, 22 | -0.28 Decreased by -21.74% | -0.23 Decreased by -94.52% |
| Aug 2, 22 | -0.26 Decreased by -136.36% | -0.22 Decreased by -82.64% |
| May 3, 22 | -0.21 Decreased by -23.53% | -0.20 Decreased by -25.00% |
| Feb 22, 22 | -0.27 Decreased by -92.86% | -0.19 Decreased by -221.61% |
| Nov 1, 21 | -0.23 Decreased by -109.09% | -0.28 Increased by +63.78% |
| Aug 3, 21 | -0.11 Increased by +63.33% | -0.20 Increased by +225.00% |
| May 4, 21 | -0.17 Increased by +65.31% | -0.22 Increased by +103.31% |
| Feb 25, 21 | -0.14 Increased by +58.82% | -0.25 Increased by +176.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 22 | 19.57 M Increased by +19.71% | -11.45 M Decreased by -71.94% | Decreased by -58.48% Decreased by -43.64% |
| Jun 30, 22 | 19.31 M Increased by +16.24% | -10.43 M Decreased by -245.35% | Decreased by -54.00% Decreased by -197.10% |
| Mar 31, 22 | 16.66 M Increased by +20.24% | -8.41 M Decreased by -82.87% | Decreased by -50.50% Decreased by -52.09% |
| Dec 31, 21 | 16.17 M Increased by +25.75% | -10.40 M Decreased by -196.86% | Decreased by -64.34% Decreased by -136.08% |
| Sep 30, 21 | 16.35 M Increased by +27.48% | -6.66 M Decreased by -156.33% | Decreased by -40.71% Decreased by -101.07% |
| Jun 30, 21 | 16.61 M Increased by +194.29% | -3.02 M Increased by +51.72% | Decreased by -18.18% Increased by +83.59% |
| Mar 31, 21 | 13.86 M Increased by +29.29% | -4.60 M Increased by +55.14% | Decreased by -33.20% Increased by +65.30% |
| Dec 31, 20 | 12.86 M Increased by +7.26% | -3.50 M Increased by +51.29% | Decreased by -27.26% Increased by +54.59% |
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to sutures and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, as well as delays gastric content emptying under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands. Additionally, the company offers X-Tack Endoscopic HeliX Tacking System, a suture-based device for closing and healing defects in the lower and upper gastrointestinal tract. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Australia, Costa Rica, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.